Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/30254
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | McCleary, Nadine J | - |
dc.contributor.author | Harmsen, William S | - |
dc.contributor.author | Haakenstad, Ellana | - |
dc.contributor.author | Cleary, James M | - |
dc.contributor.author | Meyerhardt, Jeffrey A | - |
dc.contributor.author | Zalcberg, John | - |
dc.contributor.author | Adams, Richard | - |
dc.contributor.author | Grothey, Axel | - |
dc.contributor.author | Sobrero, Alberto F | - |
dc.contributor.author | Van Cutsem, Eric | - |
dc.contributor.author | Goldberg, Richard M | - |
dc.contributor.author | Peeters, Marc | - |
dc.contributor.author | Tabernero, Josep | - |
dc.contributor.author | Seymour, Matt | - |
dc.contributor.author | Saltz, Leonard B | - |
dc.contributor.author | Giantonio, Bruce J | - |
dc.contributor.author | Arnold, Dirk | - |
dc.contributor.author | Rothenberg, Mace L | - |
dc.contributor.author | Koopman, Miriam | - |
dc.contributor.author | Schmoll, Hans-Joachim | - |
dc.contributor.author | Pitot, Henry C | - |
dc.contributor.author | Hoff, Paulo M | - |
dc.contributor.author | Tebbutt, Niall C | - |
dc.contributor.author | Masi, Gianluca | - |
dc.contributor.author | Souglakos, John | - |
dc.contributor.author | Bokemeyer, Carsten | - |
dc.contributor.author | Heinemann, Volker | - |
dc.contributor.author | Yoshino, Takayuki | - |
dc.contributor.author | Chibaudel, Benoist | - |
dc.contributor.author | deGramont, Aimery | - |
dc.contributor.author | Shi, Qian | - |
dc.contributor.author | Lichtman, Stuart M | - |
dc.date.accessioned | 2022-06-23T00:31:34Z | - |
dc.date.available | 2022-06-23T00:31:34Z | - |
dc.date.issued | 2022-03-02 | - |
dc.identifier.citation | JNCI cancer spectrum 2022; 6(2) | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/30254 | - |
dc.description.abstract | We evaluated the time to progression (TTP) and survival outcomes of second-line therapy for metastatic colorectal cancer among adults aged 70 years and older compared with younger adults following progression on first-line clinical trials. Associations between clinical and disease characteristics, time to initial progression, and rate of receipt of second-line therapy were evaluated. TTP and overall survival (OS) were compared between older and younger adults in first- and second-line trials by Cox regression, adjusting for age, sex, Eastern Cooperative Oncology Group Performance Status, number of metastatic sites and presence of metastasis in the lung, liver, or peritoneum. All statistical tests were 2-sided. Older adults comprised 16.4% of patients on first-line trials (870 total older adults aged >70 years; 4419 total younger adults aged ≤70 years, on first-line trials). Older adults and those with Eastern Cooperative Oncology Group Performance Status >0 were less likely to receive second-line therapy than younger adults. Odds of receiving second-line therapy decreased by 11% for each additional decade of life in multivariable analysis (odds ratio = 1.11, 95% confidence interval = 1.02 to 1.21, P = .01). Older and younger adults enrolled in second-line trials experienced similar median TTP and median OS (median TTP = 5.1 vs 5.2 months, respectively; median OS = 11.6 vs 12.4 months, respectively). Older adults were less likely to receive second-line therapy for metastatic colorectal cancer, though we did not observe a statistical difference in survival outcomes vs younger adults following second-line therapy. Further study should examine factors affecting decisions to treat older adults with second-line therapy. Inclusion of geriatric assessment may provide better criteria regarding the risks and benefits of second-line therapy. | en |
dc.language.iso | eng | |
dc.title | Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | JNCI cancer spectrum | en |
dc.identifier.affiliation | Austin Health | en |
dc.identifier.affiliation | Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA.. | en |
dc.identifier.affiliation | Monash University, Melbourne, Australia.. | en |
dc.identifier.affiliation | University of Sydney Medical School, Sydney, Australia.. | en |
dc.identifier.affiliation | Department of Health Science Research, Mayo Clinic, Rochester, MN, USA.. | en |
dc.identifier.affiliation | Cardiff University and Velindre Cancer Centre, Cardiff, UK.. | en |
dc.identifier.affiliation | West Cancer Center and Research Institute, OneOncology, Germantown, TN, USA.. | en |
dc.identifier.affiliation | Medical Oncology Unit, Ospedale San Martino, Genova, Italy.. | en |
dc.identifier.affiliation | University of Leuven, Leuven, Belgium.. | en |
dc.identifier.affiliation | West Virginia University Cancer Institute and the Mary Babb Randolph Cancer Center, Morgantown, WV, USA.. | en |
dc.identifier.affiliation | Department of Oncology, Antwerp University Hospital, Antwerp, Belgium.. | en |
dc.identifier.affiliation | Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Institute of Oncology Barcelona-Quiron, UVic-UCC, Barcelona, Spain.. | en |
dc.identifier.affiliation | NIHR Clinical Research Network, Leeds, UK.. | en |
dc.identifier.affiliation | Memorial Sloan Kettering Cancer Center, New York, NY, USA.. | en |
dc.identifier.affiliation | Perelman School of Medicine Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.. | en |
dc.identifier.affiliation | Instituto CUF de Oncologia, Lisbon, Portugal.. | en |
dc.identifier.affiliation | Global Product Development, Pfizer Inc, New York, NY, USA.. | en |
dc.identifier.affiliation | Department of Medical Oncology, University Medical Center Utrecht, University of Urtrecht, Utrecht, Netherlands.. | en |
dc.identifier.affiliation | Klinik fur Innere Med IV, University Clinic Halle (Saale), Halle, Germany.. | en |
dc.identifier.affiliation | Department of Oncology, Mayo Clinic, Rochester, MN, USA.. | en |
dc.identifier.affiliation | Centro de Oncologia de Brasilia do Sirio Libanes-Unidade Lago Sul, Siro Libanes, Brazil.. | en |
dc.identifier.affiliation | Department of Oncology, University of Pisa, Pisa, Italy.. | en |
dc.identifier.affiliation | Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece.. | en |
dc.identifier.affiliation | Universitatsklinikum Hamburg-Eppendorf, Hamburg-Eppendorf, Germany.. | en |
dc.identifier.affiliation | Department of Hematology/Oncology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Germany.. | en |
dc.identifier.affiliation | National Cancer Center Hospital East, Kashiwa, Japan.. | en |
dc.identifier.affiliation | Department of Medical Oncology, Institut Franco-Britannique, Levallois-Perret, France.. | en |
dc.identifier.affiliation | St. James's Hospital and University of Leeds, Leeds, UK.. | en |
dc.identifier.affiliation | Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg, Germany.. | en |
dc.identifier.affiliation | Martin Luther University, Halle, Germany.. | en |
dc.identifier.affiliation | Universidade de São Paulo Instituto do Cancer do Estado de São Paulo, São Paulo, Brazil.. | en |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/35603849/ | en |
dc.identifier.doi | 10.1093/jncics/pkac014 | en |
dc.type.content | Text | en |
dc.identifier.orcid | 0000-0003-2377-8301 | en |
dc.identifier.orcid | 0000-0002-6624-0782 | en |
dc.identifier.orcid | 0000-0003-3915-7243 | en |
dc.identifier.orcid | 0000-0002-9341-6499 | en |
dc.identifier.orcid | 0000-0001-7764-673X | en |
dc.identifier.orcid | 0000-0002-6372-1230 | en |
dc.identifier.orcid | 0000-0003-0308-8223 | en |
dc.identifier.orcid | 0000-0003-4969-2303 | en |
dc.identifier.orcid | 0000-0002-2495-8139 | en |
dc.identifier.orcid | 0000-0002-2441-9629 | en |
dc.identifier.orcid | 0000-0001-8353-4670 | en |
dc.identifier.orcid | 0000-0003-1550-1978 | en |
dc.identifier.orcid | 0000-0003-2613-5168 | en |
dc.identifier.orcid | 0000-0001-6071-7810 | en |
dc.identifier.orcid | 0000-0002-1349-3321 | en |
dc.identifier.orcid | 0000-0002-0489-4756 | en |
dc.identifier.orcid | 0000-0001-7940-9877 | en |
dc.identifier.orcid | 0000-0002-4640-8832 | en |
dc.identifier.orcid | 0000-0003-4146-6192 | en |
dc.identifier.pubmedid | 35603849 | |
local.name.researcher | Tebbutt, Niall C | |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.